Centenara Labs supports pioneers in the field of aging to transform their scientific discoveries into medicines. We are building a product pipeline comprised of potential breakthrough therapeutics that treat diseases of aging and help reduce the growing strain on global healthcare systems as the world’s population ages.
Our purpose
We aim to make hope a reality by delivering innovation that will help people to live healthier, longer lives. Our goal is to expand the health span of human beings, enabling all of us to enjoy a higher quality of life in old age, and reducing the burden of age-related diseases.
Addressing the significant strain on global health systems
In the next 20 years, the global aging population will experience an increased likelihood of “multiple-morbidity”, dealing with multiple disease diagnoses and an overall reduced quality of life.
+40%
burden of Alzheimer’s disease and related dementias
+118%
diabetes patients
+179%
cancer diagnoses
Understanding the hallmarks of aging
Aging is a complex and multifaceted phenomenon. The Hallmarks of Aging are those pathways that underlie human aging, represented within their three respective groups: primary, antagonistic and integrative.
Primary hallmarks of aging are the foundational causes of cellular damage. These are mainly related to the accumulation of DNA mutations and the impact of misfolded proteins with age. This damage triggers a dysregulation of cellular metabolism and an accumulation of senescent cells, which represent the antagonistic hallmarks of aging. These in turn cause integrative impacts, such as increased chronic inflammation throughout the body.
It is the combination of primary and antagonistic hallmarks which leads to the functional declines that are commonly observed in aging. Our goal is to develop and invest in therapies that prevent or reverse each of these hallmarks of aging, thereby expanding healthspan and promoting overall health and well-being as people age.
Addressing vision loss with two innovative programs
- Retinitis Pigmentosa: Successfully completed Phase 1b/2a clinical study, demonstrating safety and early signs of efficacy. Received FDA Fast Track and Orphan Drug Designations.
- Dry-AMD (Age-related Macular Degeneration): IND clearance achieved in October 2023. Phase 1 study planned to begin in 2025.
Targeted elimination of senescent cells for cancer treatment
- Addressing cancer escape mechanisms in Triple-Negative Breast Cancer post-standard of care with a proprietary antibody in IND-enabling studies, anticipated to enter clinical development in 2025.
Breakthrough in fibrosis treatment
- Strong anti-fibrotic effect demonstrated in fibrosis models, including IPF and CKD, supported by a novel and differentiated mechanism of action.
- Early-stage discovery platform identified 5 first-in-class therapeutic targets.
Telomere restoration program
-
- Aiming to repair shortened telomeres, offering potential breakthroughs in aging and disease treatment.
Sarcopenia
- A unique drug combination targeting multiple age-related diseases, with the lead clinical program demonstrating therapeutic potential in treating muscle weakness induced sarcopenia.
Vascular / Cognitive Program
- Targeting brain vasculature to combat age-related decline from CNS function
- Focuses on developing pro-cognitive therapies
Our Diversified Portfolio
We make healthy aging a reality by building portfolio companies focused on treatments for healthy aging. Our goal is to create a platform of portfolio companies that will lead to optimal exit scenarios after successful development, making space so that we can continue to create new portfolio companies.
This specific platform model approach spreads the risk across a variety of technologies and approaches, while providing synergies that could accelerate the speed to market in this growing field of longevity.
Clinical Stage
Endogena
Therapeutics
Targeting degenerative diseases of the eye through activation of endogenous stem cells.
EA-2353 – Retinitis Pigmentosa
Rejuvenate
Biomed
Targeting age-related muscle degeneration alongside a proprietary AI platform, CombinAge
RJx-01 – Sarcopenia
Pre-Clinical
RejuverSen
Single intervention elimination of senescent cells with applications across cancer, fibrosis and age related disease
RST-001 – Breast Cancer
RST-002 – IPF/CKD
RST-003 – Fibrosis
Telomere Program
Breakthrough restoration and reversal of prematurely damaged or shortened telomeres to treat rare genetic diseases
CCT-001 – DC/IPF
Discovery
Vascular Program
Targeting brain vasculature to improve declining CNS function caused by aging or neurodegenerative disease
CVT-001 – Neuro-degenerative Disorders
Boost
Neuroscience
Advanced screening and cell biology techniques to develop pro-cognitive therapies
BOO-1003 – Cognitive Disorders
Progress and Milestones
The timeline below showcases the progress made by our portfolio companies across their lifecycle to date.
